AnaptysBio
ANAB
207 hedge funds and large institutions have $1.55B invested in AnaptysBio in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 58 increasing their positions, 70 reducing their positions, and 20 closing their positions.
364% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $305K
155% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
16% more funds holding
Funds holding: 179 → 207 (+28)
9% more capital invested
Capital invested by funds: $1.42B → $1.55B (+$128M)
7.8% less ownership
Funds ownership: 106.02% → 98.22% (-7.8%)
17% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 70
Top Buyers
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$26.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$19.9M |
| 4 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
+$17.1M |
| 5 |
ACA
Apis Capital Advisors
New York
|
+$12.8M |
Top Sellers
ANAB Hedge Fund Activity: Q1 2026 in Review
207 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2026, worth a combined $1.55B — up 9% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ANAB positions and 20 closed out — a net gain of 31 holders — while 58 added to existing stakes and 70 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $26.6M. The largest seller was Point72 Asset Management, cutting an estimated $101M.
- 207 institutional investors held AnaptysBio (ANAB) as of Q1 2026, up from 179 in Q4 2025.
- Funds reported $1.55B of AnaptysBio stock for Q1 2026, up 9% quarter-over-quarter.
- 51 funds opened new AnaptysBio positions in Q1 2026 and 20 closed out, a net change of +31 holders.
- The largest AnaptysBio buyer in Q1 2026 was Affinity Asset Advisors, an estimated $26.6M added.
- The largest AnaptysBio seller in Q1 2026 was Point72 Asset Management, an estimated $101M sold.
Based on aggregated 13F filings for Q1 2026.